Empagliflozin for mild-to-moderate ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This early trial studies whether empagliflozin can improve ulcerative colitis symptoms and is safe for people with mild to moderate disease. If it works, it may reduce ongoing colon inflammation and help people feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with mild-to-moderate ulcerative colitis.
- Your diagnosis was confirmed with symptoms plus colon scope (endoscopy) and biopsy, to show long-lasting inflammation and rule out other causes.
- You do not have Crohn’s disease or another type of inflammatory bowel disease.
- You have never had a serious allergic reaction to empagliflozin (or its ingredients).
- You are not on dialysis and your kidney function is not severely reduced (eGFR is 20 or higher).
- You do not have long-term bladder/urinary infections or long-term genital infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
This trial tests a medicine called empagliflozin (usually used for diabetes) to see if it can help people with very advanced kidney disease and diabetes. The study will check if this drug can slow down further kidney damage and improve overall kidney health.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests if the diabetes drug empagliflozin can help reduce inflammation in people with stable coronary artery disease who are planning to have a stent placed. It may offer a new way to protect heart health.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.